VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-1.04%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$165M
AUM Growth
-$4.08M
(-2.4%)
Cap. Flow
+$1.01M
Cap. Flow
% of AUM
0.61%
Top 10 Holdings %
Top 10 Hldgs %
6.09%
Holding
488
New
53
Increased
73
Reduced
307
Closed
54
Top Buys
| 1 |
Halliburton
HAL
|
$819K |
| 2 |
Alphabet (Google) Class A
GOOGL
|
$814K |
| 3 |
Steel Dynamics
STLD
|
$798K |
| 4 |
Caterpillar
CAT
|
$792K |
| 5 |
Booking.com
BKNG
|
$789K |
Top Sells
| 1 |
Netflix
NFLX
|
$1.05M |
| 2 |
Vulcan Materials
VMC
|
$1.01M |
| 3 |
CoStar Group
CSGP
|
$998K |
| 4 |
Eli Lilly
LLY
|
$967K |
| 5 |
Ingersoll Rand
IR
|
$913K |
Sector Composition
| 1 | Healthcare | 18.63% |
| 2 | Financials | 17.26% |
| 3 | Technology | 14.89% |
| 4 | Energy | 9.42% |
| 5 | Consumer Discretionary | 8.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Denali Therapeutics
DNLI
$2.26B
| $62.8K | 0.04% |
3,045
-304
| -9% | -$6.27K |
|
402
AbCellera Biologics
ABCL
$1.26B
| $61.6K | 0.04% |
13,385
-1,329
| -9% | -$6.11K |
|
|
AGEN
403
Agenus
AGEN
$138M
| $61.1K | 0.04% |
2,702
-269
| -9% | -$6.08K |
|
404
Edgewise Therapeutics
EWTX
$1.64B
| $59.5K | 0.04% |
10,384
-1,038
| -9% | -$5.95K |
|
405
Mineralys Therapeutics
MLYS
$2.7B
| $59K | 0.04% |
6,205
-612
| -9% | -$5.82K |
|
406
ImmunityBio
IBRX
$2.27B
| $58.2K | 0.04% |
34,461
-3,427
| -9% | -$5.79K |
|
407
Protagonist Therapeutics
PTGX
$3.77B
| $57.4K | 0.03% |
3,440
-346
| -9% | -$5.77K |
|
408
4D Molecular Therapeutics
FDMT
$340M
| $57K | 0.03% |
4,479
-444
| -9% | -$5.65K |
|
409
Madrigal Pharmaceuticals
MDGL
$9.65B
| $56.7K | 0.03% |
388
-36
| -8% | -$5.26K |
|
410
Viridian Therapeutics
VRDN
$1.53B
| $54.8K | 0.03% |
3,572
-358
| -9% | -$5.49K |
|
411
Kymera Therapeutics
KYMR
$3.11B
| $53.3K | 0.03% |
3,837
-378
| -9% | -$5.25K |
|
412
Iovance Biotherapeutics
IOVA
$901M
| $51.9K | 0.03% |
11,405
-1,137
| -9% | -$5.17K |
|
413
Avidity Biosciences
RNA
$6.48B
| $51.8K | 0.03% |
8,113
-807
| -9% | -$5.15K |
|
414
ALX Oncology
ALXO
$65.3M
| $51.5K | 0.03% |
10,727
-1,067
| -9% | -$5.12K |
|
415
Arcutis Biotherapeutics
ARQT
$2.06B
| $49.1K | 0.03% |
9,248
-924
| -9% | -$4.91K |
|
416
Viking Therapeutics
VKTX
$3.03B
| $48.9K | 0.03% |
4,418
-439
| -9% | -$4.86K |
|
|
ALLK
417
DELISTED
Allakos
ALLK
| $45.8K | 0.03% |
20,177
-2,014
| -9% | -$4.57K |
|
418
Design Therapeutics
DSGN
$367M
| $43.2K | 0.03% |
18,313
-1,824
| -9% | -$4.31K |
|
419
Terns Pharmaceuticals
TERN
$632M
| $42.3K | 0.03% |
8,404
-835
| -9% | -$4.2K |
|
420
Lyell Immunopharma
LYEL
$233M
| $42.1K | 0.03% |
1,433
-143
| -9% | -$4.2K |
|
421
Fate Therapeutics
FATE
$116M
| $38.6K | 0.02% |
18,216
-1,809
| -9% | -$3.84K |
|
422
Seres Therapeutics
MCRB
$169M
| $38.5K | 0.02% |
808
-80
| -9% | -$3.81K |
|
|
MORF
423
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $37.9K | 0.02% |
1,654
-164
| -9% | -$3.76K |
|
424
Vir Biotechnology
VIR
$732M
| $35.6K | 0.02% |
3,802
-377
| -9% | -$3.53K |
|
425
Biomea Fusion
BMEA
$114M
| $35K | 0.02% |
2,543
-252
| -9% | -$3.47K |
|